CSPC Innovation(SZ:300765) YOUNG财经 漾财经·2025-11-03 05:37Core Viewpoint - The article discusses the insider trading penalty imposed on the executive director of Shijiazhuang Pharmaceutical Group, highlighting the company's normal business operations despite the legal issues faced by its executive [2][3]. Summary by Sections Insider Trading Incident - Shijiazhuang Pharmaceutical Group's executive director, Pan Weidong, was fined 5 million yuan by the China Securities Regulatory Commission (CSRC) for insider trading related to the restructuring of its subsidiary, Shijiazhuang Innovation Pharmaceutical Co., Ltd. [2] - Pan Weidong was found to have purchased 2.74258 million shares of Shijiazhuang Innovation before the public announcement of the restructuring, totaling approximately 99.9888 million yuan [2]. Company Operations and Financials - The company stated that the penalty would not negatively impact its overall business operations [3]. - Shijiazhuang Innovation's 2023 financial report indicated a revenue of 1.59 billion yuan for the first three quarters, a year-on-year increase of 7.7%, with a net loss of 24.05 million yuan, a decrease of 117.3% compared to the previous year [3][4]. Corporate Changes and Future Plans - Shijiazhuang Innovation has undergone a name change and is focusing on innovation, including acquiring equity in Jushi Biotechnology [4]. - The restructuring transaction mentioned in the penalty involved a proposed acquisition of 100% of Shijiazhuang Baike (Shandong) Biopharmaceutical Co., Ltd. for a total transaction amount of 7.6 billion yuan, which was ultimately terminated in April 2025 due to market conditions [4].